|
SRPT | Sarepta Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.85 |
| Leverage | 62.21% |
| Market Cap | $ 1.5B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -270.9m |
| Margin | -11.20% |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.